Cargando…

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid

AIM: PSMA (prostate-specific membrane antigen) is physiologically expressed in normal prostate tissue and over expressed in prostate cancer cells, therefore constituting a potential target for antibody-based radioligand therapy. Very recent imaging findings reported PSMA-PET/CT uptake in various thy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heitkötter, Birthe, Steinestel, Konrad, Trautmann, Marcel, Grünewald, Inga, Barth, Peter, Gevensleben, Heidrun, Bögemann, Martin, Wardelmann, Eva, Hartmann, Wolfgang, Rahbar, Kambiz, Huss, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839407/ https://www.ncbi.nlm.nih.gov/pubmed/29515776 http://dx.doi.org/10.18632/oncotarget.23984

Ejemplares similares

Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST
por: Heitkötter, Birthe, et al.
Publicado: (2016)

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017)

Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
por: Stock, Katharina, et al.
Publicado: (2017)

Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis – A systematic analysis of 204 cases
por: Trautmann, Marcel, et al.
Publicado: (2020)

Regulators of Actin Dynamics in Gastrointestinal Tract Tumors
por: Steinestel, Konrad, et al.
Publicado: (2015)

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy
por: Seifert, Robert, et al.
Publicado: (2021)

Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [(18)F]F-PSMA 1007 PET
por: Relt, Elisabeth, et al.
Publicado: (2022)

Evaluation of (68)Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving (177)Lu-PSMA-617 Therapy: A Radiomics Analysis
por: Roll, Wolfgang, et al.
Publicado: (2021)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy
por: Rehkämper, Jan, et al.
Publicado: (2018)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells
por: Stock, Katharina, et al.
Publicado: (2019)

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Kessel, Katharina, et al.
Publicado: (2020)

Expression levels of hnRNP K and p21(WAF1/CIP1 )are associated with resistance to radiochemotherapy independent of p53 pathway activation in rectal adenocarcinoma
por: Daskalaki, Wassiliki, et al.
Publicado: (2018)

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status
por: van Strijp, Dianne, et al.
Publicado: (2019)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

SS18-SSX drives CREB activation in synovial sarcoma
por: Cyra, Magdalene, et al.
Publicado: (2022)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
por: Kessel, Katharina, et al.
Publicado: (2021)

Focal adhesion kinase confers pro‐migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma
por: Steinestel, Konrad, et al.
Publicado: (2019)

Abdominelle Weichgewebstumoren
por: Wardelmann, Eva, et al.
Publicado: (2022)

Lack of Association between Membrane-Type 1 Matrix Metalloproteinase Expression and Clinically Relevant Molecular or Morphologic Tumor Characteristics at the Leading Edge of Invasive Colorectal Carcinoma
por: Arndt, Annette, et al.
Publicado: (2015)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions
por: Scobioala, Sergiu, et al.
Publicado: (2021)

MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas
por: Grünewald, Inga, et al.
Publicado: (2016)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Recurrent CTNNB1 mutations in craniofacial osteomas
por: Baumhoer, Daniel, et al.
Publicado: (2021)

Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma
por: Berthold, Ruth, et al.
Publicado: (2022)

Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone
por: Isfort, Ilka, et al.
Publicado: (2019)

PSMA expression by microvasculature of thyroid tumors – Potential implications for PSMA theranostics
por: Bychkov, Andrey, et al.
Publicado: (2017)

Prognostic impact of CD34 and SMA in cancer‐associated fibroblasts in stage I–III NSCLC
por: Schulze, Arik Bernard, et al.
Publicado: (2019)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

No Impact of PolySia-NCAM Expression on Treatment Response in Neuroendocrine Neoplasms of the Lung
por: Gagiannis, Daniel, et al.
Publicado: (2022)

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
por: Kessel, Katharina, et al.
Publicado: (2019)

Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?
por: Rahbar, Kambiz, et al.
Publicado: (2019)

Analysis of drug sensitivity of human high-grade osteosarcoma in a chick chorioallantoic membrane (CAM) model: a proof of principle study
por: Guder, Wiebke K., et al.
Publicado: (2020)

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
por: Seifert, Robert, et al.
Publicado: (2020)

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes
por: van Strijp, Dianne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ncp8870c3d4bonuko2e4li70vm